Loading
NRG-GY018 is the pembrolizumab twin of RUBY: immunotherapy plus chemotherapy cut the risk of progression by 70% in dMMR tumours and 46% in the rest.
NRG-GY018, also KEYNOTE-868, trial NCT03914612 run by NRG Oncology with Merck support and published in the New England Journal of Medicine in 2023, is the pembrolizumab twin of RUBY: adding immunotherapy to carboplatin and paclitaxel, followed by pembrolizumab maintenance, cut the risk of progression by seventy percent in mismatch-repair-deficient advanced or recurrent endometrial cancer and by nearly half in the rest. It randomised 816 patients analysed by mismatch repair status, met its primary progression-free survival endpoint in both cohorts, and led to FDA approval in June 2024 regardless of mismatch repair status. OnCo links it to endometrial cancer, PD-1 as a target, pembrolizumab, NRG Oncology, the dMMR term, Ramez N. Eskander and the pairing of chemotherapy with PD-1 blockade. Whether mismatch-repair-proficient patients gain a survival benefit is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
816 enrolled.
Shares Chemotherapy + PD-1/PD-L1 blockade, first-line advanced endometrial cancer, Society of Gynecologic Oncology, GOG Foundation, Endometrial cancer with no specific molecular profile.
Shares Chemotherapy + PD-1/PD-L1 blockade, first-line advanced endometrial cancer, Mismatch-repair-deficient endometrial cancer, Advanced or recurrent endometrial cancer, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR).
Shares Mismatch-repair-deficient endometrial cancer, Advanced or recurrent endometrial cancer, Endometrial cancer, Carboplatin.
Shares Endometrial cancer with no specific molecular profile, Mismatch-repair-deficient endometrial cancer, Advanced or recurrent endometrial cancer, Pembrolizumab.
Shares Mismatch-repair-deficient endometrial cancer, Advanced or recurrent endometrial cancer, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Endometrial cancer.
Shares Mismatch-repair-deficient endometrial cancer, Advanced or recurrent endometrial cancer, Endometrial cancer, Carboplatin.
Shares Mismatch-repair-deficient endometrial cancer, Endometrial cancer, Carboplatin, Pembrolizumab.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer, Paclitaxel / nab-paclitaxel, Carboplatin.